Nebacumab structure
|
Common Name | Nebacumab | ||
---|---|---|---|---|
CAS Number | 138661-01-5 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of NebacumabNebacumab (HA-1A) is a monoclonal antibody that binds to lipid A portion of endotoxin. Nebacumab can be used of research of sepsis[1][2]. |
Name | Nebacumab |
---|
Description | Nebacumab (HA-1A) is a monoclonal antibody that binds to lipid A portion of endotoxin. Nebacumab can be used of research of sepsis[1][2]. |
---|---|
Related Catalog | |
In Vitro | Nebacumab (24 μg/mL,24 小时) 在全身炎症反应综合征 (SIRS) 患者的全血中诱导产生 IL-6[2]。 Nebacumab (0-100 μg/mL) 抑制外周血单核细胞产生 TNF-α、IL-1β 和 IL-6[3]。 Nebacumab (1 和 100 μg/mL,14 天) 抑制内毒素对大鼠中耳上皮细胞的增殖和形态学影响[4]。 |
In Vivo | Nebacumab (3 mg/kg,静脉注射) 降低感染了 E.coli 的小鼠的内毒素循环水平[5]。 Animal Model: Mice infected with E.coli[5] Dosage: 3 mg/kg Administration: i.v. Result: Reduced the levels of circulating endotoxin. Reduced mesenteric lymph nodes. |
References |
No Any Chemical & Physical Properties |